Cryoport, Inc. (CYRX) Earnings
Cryoport, Inc. is expected to report next earnings on November 3, 2026 (in NaN days), with a consensus EPS estimate of $-0.19. CYRX has beaten EPS estimates in 3 of its last 12 reported quarters (average surprise -6.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-0.19 | $-0.20 | -3.5% | $49M | +1.6% |
| May 4, 2026 | $-0.20 | $-0.23 | -15.0% | $48M | +6.5% |
| Mar 3, 2026 | $-0.19 | $-0.21 | -10.5% | $45M | +1.8% |
| May 7, 2025 | $-0.23 | $-0.22 | +4.3% | $41M | -3.3% |
| Mar 4, 2025 | $-0.33 | $-0.42 | -27.3% | $60M | +1.2% |
| Nov 7, 2024 | $-0.29 | $-0.02 | +93.1% | $57M | -3.6% |
| Mar 12, 2024 | $-0.32 | $-0.51 | -59.4% | $57M | -2.0% |
| May 4, 2023 | $-0.19 | $-0.16 | +15.8% | $63M | +1.6% |
| Feb 23, 2023 | $-0.19 | $-0.24 | -26.3% | $60M | +3.3% |
| Nov 3, 2022 | $-0.14 | $-0.15 | -7.1% | $60M | -14.0% |
| Aug 4, 2022 | $-0.15 | $-0.17 | -13.3% | $64M | -3.5% |
| May 5, 2022 | $-0.20 | $-0.31 | -55.0% | $52M | -8.6% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Financial Milestones - Achieved positive adjusted EBITDA from continuing operations of $400,000, a $1.3 million year-over-year improvement, hitting an important milestone on the pathway to profitability - Generated ~$5 million in positive net cash from operating activities in H1 2026, a $17 million improvement over H1 2025 ### Industry Position & Pipeline Growth - Supports approximately 70% of the cell and gene therapy industry's global clinical trials, a commanding market position expected to drive future commercial growth - Increased the number of supported commercial cell and gene therapies to 22 after ORCA Bio gained FDA approval for TregC - Ended the quarter with 779 total global clinical trials (a net increase of 51 YoY), including 94 Phase III trials - Management expects 11 additional BLAMAA applications, 5 new therapy approvals, and 1 label/geographic expansion approval for the remainder of 2026 ### Operational & Infrastructure Milestones - Launched clinical processes for IntegraCell Cryopreservation Services in both Houston, Texas (US) and Liège, Belgium - Won a contract to support Verismo Therapeutics' two CAR-T cell therapy clinical programs - Two new state-of-the-art global supply chain centers (Paris, France and Santa Ana, California, US) are on track to open in Q4 2026, expanding CryoPort's global network - MVE Biological Solutions began shipping new products including the MVE Fusion 811 self-regenerating cryogenic freezer, and started cryogenic freezer production in China, shipping first orders of HE and OpenTops models with new Cryoverse Connect controllers ### Digital and Strategic Initiatives - Advancing enterprise digital initiatives, including use of machine learning and human-in-the-loop generative AI to automate routine tasks, analyze large datasets, manage risk, and speed decision making; already seeing measurable productivity improvements - Completed the strategic initiative to make all MVE products "smart" (data-generating and data-connected)
Guidance
- Management affirmed full-year 2026 revenue guidance at a range of $192 million to $196 million, maintaining the prior range despite a Q2 revenue beat and $97 million in H1 2026 revenue - Management reaffirmed the full-year 2026 life science products growth outlook of upper high single-digit percentage growth, implying 9-11% year-over-year product revenue growth in H2 2026 - Management expects adjusted EBITDA margins to expand further in H2 2026, driven by increased utilization of CryoPort's global supply chain network and growing operating leverage, as the company continues progress toward sustainable profitability
Segment performance
CryoPort reported total Q2 2026 revenue of $49 million. 1. Life Science Services: This segment generated 57% of total revenue, growing 15% year-over-year. Within this segment, revenue supporting commercial cell and gene therapy grew 9% YoY to $9.4 million, with the services portion growing 26% YoY. Revenue supporting cell and gene therapy clinical trials increased 12% YoY to $13.4 million. Biostorage bioservices grew 25% YoY to lead segment growth. 2. Life Science Products: This segment was flat in Q2 2026, following a strong comparative quarter in 2025, and grew 7% YoY in the first half of 2026. It is a consistent cash flow generator that provides synergies with the life science services segment.
Risks & headwinds
- Management cited ongoing geopolitical uncertainty and associated macroeconomic volatility as justifications for maintaining existing full-year guidance rather than raising it despite strong first half performance - Adoption of new standard-setting services such as IntegraCell is slowed by industry requirements for regulatory approval, updated standard operating procedures, and quality system adjustments, meaning meaningful revenue contribution will take time to materialize - Early-stage (Phase I) clinical trial activity remains softer than mid-to-late stage activity, as most available biotech funding is currently allocated to advancing Phase II and III programs toward commercialization
Analyst Q&A
Q: With a strong first half and Q2 beat, why maintain the existing full-year revenue guidance rather than raising it? What is the expectation for H2 performance? /
A: Management stated that broad geopolitical and macroeconomic uncertainties create enough uncertainty that holding the current guidance range is the most prudent approach. They confirmed that core business fundamentals remain strong, demand for both services and products is robust, and they expect existing positive demand trends to continue through the second half of 2026. Performance to date is in line with the assumptions that underpinned the original guidance range.
Q: What is the strategic rationale for starting cryogenic freezer production in China, and what is the expected revenue impact? /
A: Local production in China is intended to avoid tariffs and strengthen CryoPort's competitive position for dewars and freezers in the Chinese market. Currently, China revenue only makes up 2-3% of total company revenue, so meaningful upside will only come over the long term, and results are already progressing according to plan. Management has not yet finalized its go-to-market strategy for life science services in China and will provide updates as that develops.
Q: What are the growth prospects for the new IntegraCell cryopreservation service offering? When will it contribute meaningfully to revenue? /
A: The Houston and Liège IntegraCell sites are currently proof-of-concept locations for the broader initiative, and the company has already onboarded its first initial clients including Verismo Therapeutics. IntegraCell offers industry-standardizing benefits that will enable broader scaling of cell therapy, but adoption takes time due to required regulatory changes, quality updates and process adjustments. Management does not expect IntegraCell to be a material revenue contributor in 2026, but expects it to become a significant revenue driver over the longer term.
Q: How has AI impacted operational performance so far, and what is CryoPort's strategic approach to AI? /
A: Management confirmed that AI is already driving measurable efficiency improvements and compressed process timelines across the business. CryoPort pursues targeted AI initiatives focused specifically on improving either operational efficiency or business effectiveness, has rolled out enterprise-approved generative AI tools for all global employees, and expects the positive impact of AI on the business to grow over time, with regular updates to share with investors each quarter.